These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 20830400)

  • 1. Synthesis, single-crystal and solution structure analysis and in vitro cytotoxic activity of two novel complexes of ruthenium(II) with in situ formed flavanone-based ligands.
    Ochocki J; Kasprzak M; Chęcińska L; Erxleben A; Zyner E; Szmigiero L; Garza-Ortiz A; Reedijk J
    Dalton Trans; 2010 Oct; 39(40):9711-8. PubMed ID: 20830400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel ruthenium(III) complex with a tridentate dianionic P,O,O-ligand showing high cytotoxic activity.
    van Rijn JA; Marqués-Gallego P; Reedijk J; Lutz M; Spek AL; Bouwman E
    Dalton Trans; 2009 Dec; (48):10727-30. PubMed ID: 20023901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A straightforward and generalizable synthetic methodology for the synthesis of ruthenium(II) complexes with thioether ligands from either Ru(III) or Ru(0) precursors.
    Maiti BK; Görls H; Klobes O; Imhof W
    Dalton Trans; 2010 Jun; 39(24):5713-20. PubMed ID: 20495720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruthenium(II/III)-based compounds with encouraging antiproliferative activity against non-small-cell lung cancer.
    Nagy EM; Pettenuzzo A; Boscutti G; Marchiò L; Dalla Via L; Fregona D
    Chemistry; 2012 Nov; 18(45):14464-72. PubMed ID: 23012112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruthenium complexes in different oxidation states: synthesis, crystal structure, spectra and redox properties.
    Jabłońska-Wawrzycka A; Rogala P; Michałkiewicz S; Hodorowicz M; Barszcz B
    Dalton Trans; 2013 May; 42(17):6092-101. PubMed ID: 23381742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity.
    Bratsos I; Urankar D; Zangrando E; Genova-Kalou P; Košmrlj J; Alessio E; Turel I
    Dalton Trans; 2011 May; 40(19):5188-99. PubMed ID: 21465046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
    Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
    Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
    Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
    J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, characterization and antitumor properties of two highly cytotoxic ruthenium(iii) complexes with bulky triazolopyrimidine ligands.
    Łakomska I; Fandzloch M; Muzioł T; Lis T; Jezierska J
    Dalton Trans; 2013 May; 42(17):6219-26. PubMed ID: 23328694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, molecular structure and evaluation of new organometallic ruthenium anticancer agents.
    Camm KD; El-Sokkary A; Gott AL; Stockley PG; Belyaeva T; McGowan PC
    Dalton Trans; 2009 Dec; (48):10914-25. PubMed ID: 20023922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
    Hanif M; Nazarov AA; Hartinger CG; Kandioller W; Jakupec MA; Arion VB; Dyson PJ; Keppler BK
    Dalton Trans; 2010 Aug; 39(31):7345-52. PubMed ID: 20601976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual anti-angiogenic and cytotoxic properties of ruthenium(III) complexes containing pyrazolato and/or pyrazole ligands.
    Sun RW; Ng MF; Wong EL; Zhang J; Chui SS; Shek L; Lau TC; Che CM
    Dalton Trans; 2009 Dec; (48):10712-6. PubMed ID: 20023898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proapoptotic activity in vitro of two novel ruthenium(II) complexes with flavanone-based ligands that overcome cisplatin resistance in human bladder carcinoma cells.
    Kasprzak MM; Szmigiero L; Zyner E; Ochocki J
    J Inorg Biochem; 2011 Apr; 105(4):518-24. PubMed ID: 21334279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A.
    Trávníček Z; Matiková-Mal'arová M; Novotná R; Vančo J; Stěpánková K; Suchý P
    J Inorg Biochem; 2011 Jul; 105(7):937-48. PubMed ID: 21536006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural diversity in manganese, iron and cobalt complexes of the ditopic 1,2-bis(2,2'-bipyridyl-6-yl)ethyne ligand and observation of epoxidation and catalase activity of manganese compounds.
    Madhu V; Ekambaram B; Shimon LJ; Diskin Y; Leitus G; Neumann R
    Dalton Trans; 2010 Aug; 39(31):7266-75. PubMed ID: 20582360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic strategies towards ruthenium-porphyrin conjugates for anticancer activity.
    Gianferrara T; Bratsos I; Iengo E; Milani B; Ostrić A; Spagnul C; Zangrando E; Alessio E
    Dalton Trans; 2009 Dec; (48):10742-56. PubMed ID: 20023904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: a new strategy that might lead to improved activity.
    Bratsos I; Serli B; Zangrando E; Katsaros N; Alessio E
    Inorg Chem; 2007 Feb; 46(3):975-92. PubMed ID: 17257042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly active neutral ruthenium(II) arene complexes: synthesis, characterization, and investigation of their anticancer properties.
    Ludwig G; Kaluđerović GN; Bette M; Block M; Paschke R; Steinborn D
    J Inorg Biochem; 2012 Aug; 113():77-82. PubMed ID: 22698819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising anticancer mono- and dinuclear ruthenium(III) dithiocarbamato complexes: systematic solution studies.
    Nagy EM; Nardon C; Giovagnini L; Marchiò L; Trevisan A; Fregona D
    Dalton Trans; 2011 Nov; 40(44):11885-95. PubMed ID: 21971872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
    Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
    J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.